2025: A Year of Progress for mAbsolve
2025 has been an important year for mAbsolve. We are pleased to report that two of our commercial ...
Read More mAbsolve patent update – coverage extended
With the grant of additional patents in the USA (US1249744) and Japan (JP7791867), mAbsolve's patent coverage has been ...
Read More Systematic analysis of Fc silencing mutations
Today mAbsolve along with collaborators at RIC and Protein Stable, published a peer-reviewed article analysing over 70 different ...
Read More UMass Chan Medical School licenses STR
The Nonhuman Primate Reagent Resource (NHPRR), part of the University of Massachusetts Medical School, and mAbsolve, developers of ...
Read More Living in LALA land?
mAbsolve CEO has today published a review on the history of antibody Fc silencing. This covers Geoff's personal ...
Read More mAbsolve patent update
mAbsolve has now had patents for the STR silencing mutations granted in the United States (US12037380B2), Canada (CA3179582), ...
Read More Antibody Solutions Licenses STR from mAbsolve
Antibody Solutions have licensed our STR technology to provide their clients with access to this cutting edge technology ...
Read More mAbsolve to exhibit at Festival of Biologics 2023
mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will ...
Read More MHRA Licenses Novel Fc Silencing Technology from mAbsolve
The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold ...
Read More